Merz Expects U.S. to Honor EU Trade Pact After Drug Probe

Germany's Chancellor insists Washington must abide by the existing US-EU trade agreement after the U.S. Trade Representative launches a Section 301 pharmaceutical probe targeting Berlin's drug pricing system.

Lead

BERLIN, June 19, 2026 — German Chancellor Friedrich Merz said Friday he expects the United States to abide by the US-Germany trade pact anchored in the broader EU-US trade agreement, after U.S. Trade Representative Jamieson Greer opened a formal pharmaceutical probe into Berlin's drug pricing practices. The Section 301 investigation, initiated June 18, examines whether Germany's reimbursement system constitutes an unreasonable or discriminatory burden on U.S. commerce — and sets the stage for potential retaliatory tariffs on German goods if findings go against Berlin.

What Happened

The U.S. Trade Representative announced the Section 301 probe citing what it described as Germany's "persistent underpayment for innovative pharmaceutical products." Washington's central argument: Germany's price-control mechanisms force American patients and pharmaceutical companies to disproportionately subsidize global drug research and development costs.

The investigation was directly linked to Germany's April 2026 health insurance reform, which Merz himself labeled "historic." That legislation, passed by the German Cabinet, targets savings of more than €16 billion through lower insurance premiums and steeper mandatory discounts on the pharmaceutical industry. USTR Greer called the package "a serious step backwards," expressing concern that Berlin was accelerating legislation designed to suppress spending on innovative medicines.

Under Section 301 of the U.S. Trade Act, the USTR holds authority to investigate foreign trade practices deemed unfair, discriminatory, or a burden on U.S. commerce, and to impose tariffs or other trade restrictions if the inquiry finds sufficient grounds. A public comment docket opens June 25, 2026, written submissions are due August 10, and a formal hearing is scheduled for September 22, 2026.

Merz's Response and the Jurisdictional Argument

Speaking Friday, Chancellor Merz pushed back firmly. He stated that Germany assumes the United States will honor the trade agreement already in force with the European Union, and argued that health insurance reimbursement policy sits squarely within national jurisdiction — beyond the reach of unilateral U.S. trade action.

The position signals a dual-track defense: invoking the existing US-EU framework as a legal ceiling on Washington's leverage, while asserting sovereign authority over domestic healthcare financing. Germany's drug pricing architecture — codified under the Act on the Reform of the Market for Medicinal Products, known as AMNOG — involves negotiated discounts between statutory health insurers and manufacturers. U.S. industry groups have long argued the structure amounts to an implicit subsidy extracted from the American market.

The U.S. Chamber of Commerce formally welcomed the Section 301 investigation, adding institutional weight to Washington's position and signaling that the pharmaceutical sector will engage aggressively in the public comment process.

Strategic and Trade Context

The US-Germany trade pact operates within the EU-U.S. framework finalized in July 2025, when European Commission President Ursula von der Leyen and President Trump reached a deal that resolved escalating tariff tensions. That agreement followed a 90-day pause on threatened 30% duties against EU goods, a period during which both sides engaged in intensive negotiations.

The bilateral pharmaceutical supply chain runs in both directions, complicating any retaliatory calculus. Several major U.S. drugmakers source active ingredients and conduct late-stage manufacturing in Germany; blanket tariffs would raise costs and disrupt logistics for global pharmaceutical companies operating across both markets.

Geopolitical Dimension

The pharmaceutical probe arrives at a sensitive moment for international trade news and transatlantic relations. Berlin's position carries structural weight inside the EU: a ruling or agreement that forces Germany to accept external oversight of health reimbursements would set a precedent affecting France, Italy, the Netherlands, and other member states with similarly negotiated drug pricing systems. Brussels is expected to monitor the process closely.

German pharmaceutical companies had already warned in April that the health reform's steeper discounts could lead to delayed or withdrawn drug launches in Germany — a signal that domestic policy was already straining the sector before Washington's intervention. The Section 301 probe adds a geopolitical dimension to what had previously been a domestic policy debate.

What Comes Next

After the September 2026 hearing, the USTR will assess findings and determine whether trade measures are warranted — a process that typically extends over several additional months. Parallel consultations between Washington and Berlin could produce a negotiated outcome before any formal tariff action. Merz's framing of the US-EU trade deal as a binding constraint on unilateral measures will be tested in that process.

Outlook

The Merz drug news and U.S. pharmaceutical probe together mark a significant escalation in transatlantic trade friction, with a formal legal process now underway. Berlin's invocation of the US-Germany trade pact as a shield against unilateral action defines the opening position for what could become a protracted negotiation. With a September hearing, months of deliberation ahead, and the broader EU framework in play, the resolution of this dispute will shape pharmaceutical trade policy and drug pricing norms across the Atlantic well into 2027.